GC Cell-Artiva-MSD’s 'CAR-NK' co-R&D deal terminated
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.06.28 05:09:56
가나다라
0
MSD notifies Artiva Biotherapeutics of licensing termination…Artiva and GC Cell’s research automatically ended
”Not obligated to return the upfront payment of US$15 million…GC Cell and Artiva will continue the CAR-NK research”
▲Despite the recent termination of the collaborative R&D agreement with MSD, GC Cell and Artiva will continue their collaborative research on ‘CAR-NK solid tumor treatment.’
GC Cell and Artiva Biotherapeutic’s collaborative research and development (R&D) agreement with MSD for ‘CAR-NK solid tumor treatment’ has been terminated. MSD informed Artiva Biotherapeutic, GC Cell’s U.S. subsidiary, of the contract termination. As a result, Artiva Biotherapeutic and GC Cell’s research agreement has been automatically ended.
On June 25th, GC Cell announced a collaborative R&D agreement with Artiva Biotherapeutic for three treatments for CAR-NK solid tumors has terminated.
In January 2021, GC Cell signed a collaborative R&D agreement with Artiva for CAR-NK cell treatment targeting solid tumors. GC Cell received an upfront payment of US$15 million (
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)